CoChat
Sign Up
Cited by 6Cancer-related molecular mechanisms researchMicroRNA in disease regulationCircular RNAs in diseases

Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression

Open access
Guo, Kai, Fang, Lingling, Li, Mingjian, Li, Aizheng, Liu, Na·2023·Behavioural Neurology
DOI 10.1155/2023/4190849PMC PMC9904930
Open this paper in CoChat — free accountOpen PDF

Abstract

Glioblastoma (GBM) is a highly malignant cancer, the prognosis of which is pretty poor. Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs, which play important roles in carcinogenesis process of many cancers including GBM. In this study, we want to clarify the expression, biological function, and molecular mechanism of lncRNA KTN1 antisense RNA 1 (KTN1-AS1) in GBM tumor progression. We found that KTN1-AS1 expression was upregulated in GBM tissues and cell lines. KTN1-AS1 played oncogenic roles to facilitate proliferation, migration, and invasion of GBM cells. Then, we revealed that miR-505 was a target of KTN1-AS1, and its expression was decreased in GBM. KTN1-AS1 contributed to GBM progression by mediating miR-505. Finally, we demonstrated that KTN1-AS1 upregulated some target oncogenes of miR-505 including ZEB2, HMGB1, and RUNX2 in GBM cells. All in all, we concluded that the highly expressed KTN1-AS1 in GBM played oncogenic roles to facilitate GBM progression by targeting miR-505.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2023/4190849

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Reduced expression of miR-505-3p enhances tumorigenic properties, including cell proliferation, colony formation, cell cycle progression, tumor cell migration, metastasis, and tumor growth in vivo.

    “Reduced expression of miR-505-3p enhances tumorigenic properties, including cell proliferation, colony formation, cell cycle progression, tumor cell migration, metastasis, and tumor growth in vivo (19)(20)(21).”

    From Functional interaction between miR-505-3p and miR-21 contributes to GBM suppression (2026) · cites this paper as [19]

    Results §3.4 (page not specified) reports that inhibiting miR-505 restored proliferation, migration, and invasion in GBM cells when KTN1-AS1 was silenced. The paper does not report that reduced miR-505-3p enhances colony formation, cell-cycle progression, metastasis, or tumor growth in vivo. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [2]Tan A. C. Ashley D. M. López G. Y. Malinzak M. Friedman H. S. Khasraw M. Management of glioblastoma: state of the art and future directions CA: a Cancer Journal for Clinicians 2020 70 4 299 312 10.3322/caac.21613 32478924 · DOI
  2. [3]Janjua T. I. Rewatkar P. Ahmed-Cox A. Frontiers in the treatment of glioblastoma: past, present and emerging Advanced Drug Delivery Reviews 2021 171 108 138 10.1016/j.addr.2021.01.012 33486006 · DOI
  3. [4]White K. Connor K. Clerkin J. New hints towards a precision medicine strategy for IDH wild-type glioblastoma Annals of Oncology 2020 31 12 1679 1692 10.1016/j.annonc.2020.08.2336 32918998 · DOI
  4. [5]Ali T. Grote P. Beyond the RNA-dependent function of LncRNA genes eLife 2020 9 p. 9 10.7554/eLife.60583 PMC7584451 33095159 · DOI
  5. [6]Fu D. Shi Y. Liu J. Targeting long non-coding RNA to therapeutically regulate gene expression in cancer Molecular Therapy Nucleic Acids 2020 21 712 724 10.1016/j.omtn.2020.07.005 32771923 PMC7412722 · DOI
  6. [7]Peng Z. Liu C. Wu M. New insights into long noncoding RNAs and their roles in glioma Molecular Cancer 2018 17 1 p. 61 10.1186/s12943-018-0812-2 2-s2.0-85042187958 29458374 PMC5817731 · DOI
  7. [8]Tay Y. Rinn J. Pandolfi P. P. The multilayered complexity of ceRNA crosstalk and competition Nature 2014 505 7483 344 352 10.1038/nature12986 2-s2.0-84892573723 24429633 PMC4113481 · DOI · Paper page
  8. [9]Yu Y. Gao F. He Q. Li G. Ding G. lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143 Molecular Therapy Nucleic Acids 2020 19 751 758 10.1016/j.omtn.2019.11.021 31954329 PMC6962633 · DOI
  9. [10]Hu X. Xiang L. He D. The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling Clinical Science 2021 135 3 555 574 10.1042/CS20200908 33480975 · DOI
  10. [11]Li C. Zhao W. Pan X. LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1 Oncogene 2020 39 39 6157 6171 10.1038/s41388-020-01427-4 32820252 · DOI
  11. [12]Liu C. Li X. Hao Y. STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis Aging 2020 12 9 8680 8701 10.18632/aging.103191 32396871 PMC7244022 · DOI
  12. [13]Karsy M. Guan J. Cohen A. L. Jensen R. L. Colman H. New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M Current Neurology and Neuroscience Reports 2017 17 2 p. 19 10.1007/s11910-017-0722-5 2-s2.0-85015053977 28271343 · DOI
  13. [14]Stackhouse C. T. Gillespie G. Y. Willey C. D. Exploring the roles of lncRNAs in GBM pathophysiology and their therapeutic potential Cell 2020 9 11 p. 2369 PMC7692132 33126510
  14. [15]Paulmurugan R. Malhotra M. Massoud T. F. The protean world of non-coding RNAs in glioblastoma Journal of Molecular Medicine 2019 97 7 909 925 10.1007/s00109-019-01798-6 2-s2.0-85066306678 31129756 · DOI
  15. [16]Xu Z. Zhang D. Zhang Z. MicroRNA-505, suppressed by oncogenic long non-coding RNA LINC01448, acts as a novel suppressor of glycolysis and tumor progression through inhibiting HK2 expression in pancreatic cancer Frontiers in Cell and Development Biology 2020 8 p. 625056 PMC7843961 33520999
  16. [17]Zhang Y. Lv F. Qiao L. Zhao Q. MiR-505 inhibits prostate cancer cell invasion, metastasis and epithelial-to-mesenchymal transition through targeting HMGB-1 Journal of BUON 2020 25 4 2036 2044 33099950
  17. [18]Zhu P. Liu Z. Huang H. Zhong C. Zhou Y. MiRNA505/NET1 axis acts as a CD8 T-TIL regulator in non-small cell lung cancer Oncotargets and Therapy 2020 13 9785 9795 10.2147/OTT.S265859 33061457 PMC7534871 · DOI
  18. [19]Chi X. Jiang Y. Chen Y. microR-505/heterogeneous nuclear ribonucleoprotein M inhibits hepatocellular carcinoma cell proliferation and induces cell apoptosis through the Wnt/β-catenin signaling pathway Biomarkers in Medicine 2020 14 11 981 996 10.2217/bmm-2019-0511 32940078 · DOI
  19. [20]Zhang C. Yang X. Fu C. Liu X. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway Gene 2018 672 172 179 10.1016/j.gene.2018.06.030 2-s2.0-85048714575 29906532 · DOI · Paper page
  20. [21]Feng S. Liu W. Bai X. LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer Cancer Letters 2019 465 105 117 10.1016/j.canlet.2019.09.002 2-s2.0-85071973047 31499118 · DOI
  21. [22]Li L. Lv G. Wang B. Ma H. Long noncoding RNA LINC00525 promotes the aggressive phenotype of chordoma through acting as a microRNA-505-3p sponge and consequently raising HMGB1 expression Oncotargets and Therapy 2020 13 9015 9027 10.2147/OTT.S268678 32982292 PMC7490091 · DOI
  22. [23]Zhao P. Guan H. Dai Z. Ma Y. Zhao Y. Liu D. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis European Journal of Pharmacology 2019 865 p. 172778 10.1016/j.ejphar.2019.172778 31705901 · DOI
  23. [24]Fardi M. Mo A. Baradaran B. The crucial role of ZEB2: from development to epithelial-to-mesenchymal transition and cancer complexity Journal of Cellular Physiology 2019 234 9 14783 14799 10.1002/jcp.28277 2-s2.0-85061776287 30773635 · DOI
  24. [25]Tripathi A. Shrinet K. Kumar A. HMGB1 protein as a novel target for cancer Toxicology Reports 2019 6 253 261 10.1016/j.toxrep.2019.03.002 2-s2.0-85062718918 30911468 PMC6416660 · DOI
  25. [26]Gao X. Y. Zang J. Zheng M. H. Temozolomide treatment induces HMGB1 to promote the formation of glioma stem cells via the TLR2/NEAT1/Wnt pathway in glioblastoma Frontiers in Cell and Development Biology 2021 9 p. 620883 PMC7891666 33614649
  26. [27]Yamada D. Fujikawa K. Kawabe K. Furuta T. Nakada M. Takarada T. RUNX2 promotes malignant progression in glioma Neurochemical Research 2018 43 11 2047 2054 10.1007/s11064-018-2626-4 2-s2.0-85053034891 30203400 · DOI

Cited by

Sorted by citations

Authors
Guo, K., Fang, L., Li, M., Li, A., & Liu, N.
Affiliations
  • Weifang People's Hospital (CN)
  • Department of Neurology, Anqiu People’s Hospital, Anqiu, Shandong 262100, China
Corresponding author
Liu, Na
ORCID
Venue
Behavioural Neurology
Publisher
Wiley
Published
2023-01-31
Volume
2023
Pages
1-11
ISSN
  • 0953-4180 (ISSN-L)
  • 1875-8584
DOI
10.1155/2023/4190849
PMC
PMC9904930
OpenAlex
W4318822020
Cited by
6
References
1
Citations by year
2026: 1 · 2024: 3 · 2023: 2
FWCI
0.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Behavioural Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Weifang Science and Technology Bureau (JB33301)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Circular RNAs in diseases
Keywords
glioblastoma, long non-coding RNA, miR-505, microRNA sponge, tumor progression, cell proliferation, cell migration and invasion, ZEB2, HMGB1, Runx2, oncogenic lncRNA
MeSH terms
Glioblastoma, Humans, Membrane Proteins, Prognosis, MicroRNAs, Cell Line, Tumor, RNA, Long Noncoding

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review